WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 30, 2025.
First quarter financial summary
2025 guidance summary
"Our performance for the first quarter was in line with our expectations" said Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer. "Were it not for the impact of tariffs enacted since the issuance of our previous guidance, we project that our full-year results for 2025 would fall within our previously stated guidance ranges. We are evaluating strategies to mitigate our exposure to tariffs and remain highly focused on executing our plan for the year. Finally, in-line with our disciplined capital allocation strategy, we completed our previously announced $300 million accelerated share repurchase on April 9, 2025.”
"On our last call, we announced our intended separation of Teleflex into two independent publicly traded companies, which we believe will enhance value for all Teleflex shareholders. As we expected, since announcing the intended separation, we have received significant third-party interest in acquiring NewCo. With the full support and oversight of the Board, management are continuing to actively explore all options for NewCo with the goal of maximizing shareholder value, including evaluating the potential sale of NewCo in parallel with the potential spin transaction."
NET REVENUE BY SEGMENT
The following table provides information regarding net revenues in each of the Company's reportable operating segments for the three months ended March 30, 2025 and the comparable prior year period on both a GAAP and adjusted constant currency basis.
| Three Months Ended | % Increase / (Decrease) | ||||||||
| March 30, 2025 | March 31, 2024 | Reported Revenue Growth | Currency Impact | Adjusted Constant Currency Revenue Growth | |||||
| Americas | $475.7 | $494.0 | (3.7)% | (0.5)% | (3.2)% | ||||
| EMEA | 151.2 | 159.6 | (5.3)% | (2.5)% | (2.8)% | ||||
| Asia | 73.8 | 84.2 | (12.4)% | (2.7)% | (9.7)% | ||||
| Consolidated | $700.7 | $737.8 | (5.0)% | (1.2)% | (3.8)% | ||||
NET REVENUE BY GLOBAL PRODUCT CATEGORY
The following table provides information regarding net revenues in each of the Company's global product categories for the three months ended March 30, 2025 and the comparable prior year period on both a GAAP and adjusted constant currency basis.
| Three Months Ended | % Increase / (Decrease) | ||||||||
| March 30, 2025 | March 31, 2024 | Reported Revenue Growth | Currency Impact | Adjusted Constant Currency Revenue Growth | |||||
| Vascular Access | $182.4 | $181.4 | 0.6% | (1.3)% | 1.9% | ||||
| Interventional | 137.5 | 134.7 | 2.1% | (1.1)% | 3.2% | ||||
| Anesthesia | 86.6 | 96.4 | (10.1)% | (1.5)% | (8.6)% | ||||
| Surgical | 105.8 | 105.5 | 0.2% | (1.8)% | 2.0% | ||||
| Interventional Urology | 71.0 | 79.7 | (11.0)% | (0.3)% | (10.7)% | ||||
| OEM | 63.9 | 87.7 | (27.2)% | (0.4)% | (26.8)% | ||||
| Other | 53.5 | 52.4 | 1.9% | (2.6)% | 4.5% | ||||
| Consolidated | $700.7 | $737.8 | (5.0)% | (1.2)% | (3.8)% | ||||
OTHER FINANCIAL HIGHLIGHTS
2025 OUTLOOK
The Company raised its full year 2025 revenue growth outlook on a GAAP basis to a range of 1.28% to 2.28% from a range of (0.35)% to 0.65%, reflecting our estimate of an approximately 0.17% negative impact of foreign exchange rate fluctuations as compared to our previous estimate of a 1.80% negative impact. On an adjusted constant currency basis, the Company maintained its full year 2025 revenue growth outlook of 1.00% to 2.00%.
The Company lowered its full year 2025 GAAP diluted earnings per share from continuing operations outlook to a range of $6.51 to $6.91 from a range of $8.85 to $9.25 due to the assumption of currently enacted tariffs and separation and acquisition-related expenses. The Company lowered its full year 2025 adjusted diluted earnings per share from continuing operations guidance to a range of $13.20 to $13.60 from a range of $13.95 to $14.35, representing a decrease of 5.8% to 2.9% year-over-year. The reduction in adjusted earnings per share is due to the assumption of currently announced tariffs partially offset by the $300 million share repurchase, expense control, and a small benefit from foreign exchange.
Forecasted 2025 Adjusted Constant Currency Revenue Growth Reconciliation
| Low | High | ||
| Forecasted 2025 GAAP revenue growth | 1.28% | 2.28% | |
| Estimated impact of foreign currency exchange rate fluctuations | (0.17)% | (0.17)% | |
| Prior year Italian payback measure adjustment | 0.45% | 0.45% | |
| Forecasted 2025 adjusted constant currency revenue growth | 1.00% | 2.00% |
Forecasted 2025 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation
| Low | High | ||||
| Forecasted GAAP diluted earnings per share from continuing operations | $6.51 | $6.91 | |||
| Restructuring, restructuring related, and impairment items, net of tax | $0.42 | $0.42 | |||
| Acquisition, integration and divestiture related items, net of tax | $0.01 | $0.01 | |||
| Separation costs, net of tax | $1.78 | $1.78 | |||
| ERP Implementation, net of tax | $0.48 | $0.48 | |||
| MDR, net of tax | $0.16 | $0.16 | |||
| Intangible amortization expense, net of tax | $3.86 | $3.86 | |||
| Tax adjustments | $(0.02) | $(0.02) | |||
| Forecasted adjusted diluted earnings per share from continuing operations, net of tax | $13.20 | $13.60 | |||
CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION
A webcast of Teleflex's first quarter 2025 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on May 1, 2025.
An audio replay of the investor call will be available beginning at 11:00 am ET on May 1, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The confirmation code is 69028.
ADDITIONAL NOTES
References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.
In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.
Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.
NOTES ON NON-GAAP FINANCIAL MEASURES
We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP”. In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: adjusted revenue, adjusted constant currency revenue growth and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.
Tables reconciling changes in historical adjusted constant currency net revenues and adjusted net revenues to historical GAAP net revenues and historical adjusted diluted earnings per share from continuing operations to historical GAAP diluted earnings per share from continuing operations are set forth below.
Adjusted revenue: This non-GAAP measure is based upon net revenues, adjusted to exclude the impact in the year ended December 31, 2024 of an increase in our reserves, and corresponding reduction to revenue within our EMEA segment, for prior years. The reserve relates to the Italian payback measure, a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a ruling from the Italian courts, we recognized an increase in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years. The prior year amounts do not represent normal adjustments to revenue, are not expected to recur in future periods and are not recurring in nature, making it difficult to contribute to a meaningful evaluation of our operating performance. Accordingly, management has excluded the $13.8 million prior year amount as it is not indicative of our underlying core performance or business trends.
Adjusted constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.
Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.
Restructuring, restructuring related, and impairment items - Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program. Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges, including those related to goodwill and other assets, occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.
Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.
Separation costs - These adjustments represents direct costs related to our recently announced strategic actions to separate Teleflex into RemainCo and NewCo and primarily consist of consulting, legal, tax, and other professional advisory services. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction has been completed.
Italian payback measure - These adjustments represent the exclusion of the impact from increases in our reserves related to the Italian payback measure pertaining to prior years as described in Adjusted revenue.
Pension termination and related charges - These adjustments represent charges associated with the planned termination of the Teleflex Incorporated Retirement Income Plan, a frozen U.S. defined benefit pension plan, and related direct incremental expenses including certain charges stemming from the liquidation of surplus plan assets. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur once the plan termination process has been completed. Accordingly, management has excluded these amounts to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.
European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).
Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.
ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.
Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.
Reconciliation of Net Revenue (Dollars in millions)
Net revenue by segment
| Three Months Ended | % Increase / (Decrease) | ||||||||||||||||||
| March 30, 2025 | March 31, 2024 | ||||||||||||||||||
| Reported revenue | Adjustment | Adjusted Revenue | Reported revenue | Adjustment | Adjusted Revenue | Reported Revenue Growth | Currency Impact | Adjustment impact | Adjusted Constant Currency Revenue Growth | ||||||||||
| Americas | $475.7 | $— | $475.7 | $494.0 | $— | $494.0 | (3.7)% | (0.5)% | —% | (3.2)% | |||||||||
| EMEA | 151.2 | — | 151.2 | 159.6 | — | 159.6 | (5.3)% | (2.5)% | —% | (2.8)% | |||||||||
| Asia | 73.8 | — | 73.8 | 84.2 | — | 84.2 | (12.4)% | (2.7)% | —% | (9.7)% | |||||||||
| Consolidated | $700.7 | $— | $700.7 | $737.8 | $— | $737.8 | (5.0)% | (1.2)% | —% | (3.8)% | |||||||||
Net revenue by global product category
| Three Months Ended | % Increase / (Decrease) | ||||||||||||||||||
| March 30, 2025 | March 31, 2024 | ||||||||||||||||||
| Reported revenue | Adjustment | Adjusted Revenue | Reported revenue | Adjustment | Adjusted Revenue | Reported Revenue Growth | Currency Impact | Adjustment impact | Adjusted Constant Currency Revenue Growth | ||||||||||
| Vascular Access | $182.4 | $— | $182.4 | $181.4 | $— | $181.4 | 0.6% | (1.3)% | —% | 1.9% | |||||||||
| Interventional | 137.5 | — | 137.5 | 134.7 | — | 134.7 | 2.1% | (1.1)% | —% | 3.2% | |||||||||
| Anesthesia | 86.6 | — | 86.6 | 96.4 | — | 96.4 | (10.1)% | (1.5)% | —% | (8.6)% | |||||||||
| Surgical | 105.8 | — | 105.8 | 105.5 | — | 105.5 | 0.2% | (1.8)% | —% | 2.0% | |||||||||
| Interventional Urology | 71.0 | — | 71.0 | 79.7 | — | 79.7 | (11.0)% | (0.3)% | —% | (10.7)% | |||||||||
| OEM | 63.9 | — | 63.9 | 87.7 | — | 87.7 | (27.2)% | (0.4)% | —% | (26.8)% | |||||||||
| Other | 53.5 | — | 53.5 | 52.4 | — | 52.4 | 1.9% | (2.6)% | —% | 4.5% | |||||||||
| Consolidated | $700.7 | $— | $700.7 | $737.8 | $— | $737.8 | (5.0)% | (1.2)% | —% | (3.8)% | |||||||||
Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)
| Three Months Ended March 30, 2025 | ||||||||
| Gross margin | Selling, general and administrative expenses (1) | Research and development expenses (1) | Operating margin (2) | Income before income taxes | Income tax expense | Effective income tax rate | Diluted earnings per share from continuing operations | |
| GAAP Basis | 55.6% | 31.8% | 5.2% | 17.9% | $108.9 | $13.8 | 12.7% | $2.07 |
| Adjustments | ||||||||
| Restructuring, restructuring related, and impairment items (A) | 0.7 | — | — | 0.9 | 6.9 | 1.2 | 0.13 | |
| Acquisition, integration and divestiture related items (B) | — | 2.5 | — | (2.5) | (17.8) | 0.8 | (0.42) | |
| Separation costs | — | — | — | 0.5 | 3.2 | — | 0.07 | |
| ERP implementation | — | (0.8) | — | 0.8 | 5.9 | 1.0 | 0.11 | |
| MDR | — | — | (0.2) | 0.2 | 1.3 | — | 0.03 | |
| Intangible amortization expense | 4.1 | (2.8) | — | 6.9 | 47.9 | 5.3 | 0.93 | |
| Tax adjustments | — | — | — | — | — | 0.7 | (0.01) | |
| Adjustments total | 4.8 | (1.1) | (0.2) | 6.8 | 47.4 | 9.0 | 0.84 | |
| Adjusted basis | 60.4% | 30.7% | 5.0% | 24.7% | $156.3 | $22.8 | 14.5% | $2.91 |
| Three Months Ended March 31, 2024 | ||||||||
| Gross margin | Selling, general and administrative expenses (1) | Research and development expenses (1) | Operating margin (2) | Income before income taxes | Income tax expense | Effective income tax rate | Diluted earnings per share from continuing operations | |
| GAAP Basis | 56.4% | 51.6% | 5.1% | (0.6)% | $(25.8) | $(41.6) | 161.0% | $0.33 |
| Adjustments | ||||||||
| Restructuring, restructuring related, and impairment items (A) | 0.3 | (0.1) | — | 0.8 | 5.8 | 1.0 | 0.10 | |
| Acquisition, integration and divestiture related items (B) | 0.2 | (0.2) | — | 0.5 | 3.4 | 0.4 | 0.06 | |
| ERP Implementation | — | — | — | — | 0.1 | — | — | |
| MDR | — | — | (0.5) | 0.3 | 3.3 | — | 0.07 | |
| Pension termination costs | — | (18.8) | — | 18.8 | 138.5 | 58.2 | 1.70 | |
| Intangible amortization expense | 4.2 | (2.7) | — | 6.8 | 50.1 | 5.1 | 0.95 | |
| Adjustments total | 4.7 | (21.8) | (0.5) | 27.2 | 201.2 | 64.7 | 2.88 | |
| Adjusted basis | 61.1% | 29.8% | 4.6% | 26.6% | $175.4 | $23.1 | 13.2% | $3.21 |
| Notes: | (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues. |
| (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues. | |
| Totals may not sum due to rounding. | |
Tickmarks to Reconciliation Tables
(A) Restructuring, restructuring related, and impairment items – For the three months ended March 30, 2025, pre-tax restructuring charges were $1.5 million, restructuring related charges were $5.4 million, and there were no pre-tax impairment charges. For the three months ended March 31, 2024, pre-tax restructuring charges were $0.5 million, restructuring related charges were $3.2 million, and pre-tax impairment charges were $2.1 million.
(B) Acquisition, integration and divestiture related items – For the three months ended March 30, 2025, these charges primarily related to the pending acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG, which is inclusive of $4.5 million of acquisition costs offset by the recognition of a $22.5 million benefit related to non-designated foreign currency forward contracts entered into to economically hedge against the foreign currency exposure associated with the cash consideration required to complete the acquisition. For the three months ended March 31, 2024, these charges primarily related to the acquisition of Palette Life Sciences AB.
ABOUT TELEFLEX INCORPORATED
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
CAUTION CONCERNING FORWARD-LOOKING INFORMATION
This press release contains forward-looking statements, including, but not limited to, forecasted 2025 GAAP and adjusted constant currency revenue growth and GAAP and adjusted diluted earnings per share; our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2025 financial results; statements about our plans to separate certain of our businesses into an independent company, the expected timetable for completing the transaction, the tax-free nature of the transaction, the future financial and operating performance of each company following the transaction, the benefits and synergies of the transaction, strategic and competitive advantages of each company, and future growth and other opportunities for each company. Actual results could differ materially from those in the forward-looking statements due to, among other things, any changes in or abandonment of the proposed transaction and our ability to satisfy the conditions to the proposed transaction; unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the transaction; customer and shareholder reaction to the transaction; disruption from the transaction making it more difficult to maintain business and operational relationships; significant transaction costs; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; the inability of acquired businesses to generate revenues in accordance with our expectations; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.
| TELEFLEX INCORPORATED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) | |||||||
| Three Months Ended | |||||||
| March 30, 2025 | March 31, 2024 | ||||||
| (Dollars and shares in thousands, except per share) | |||||||
| Net revenues | $ | 700,669 | $ | 737,849 | |||
| Cost of goods sold | 311,230 | 321,715 | |||||
| Gross profit | 389,439 | 416,134 | |||||
| Selling, general and administrative expenses | 222,710 | 242,830 | |||||
| Research and development expenses | 36,404 | 37,299 | |||||
| Pension settlement charge | — | 138,139 | |||||
| Restructuring charges, separation costs and impairment charges | 4,755 | 2,659 | |||||
| Income (loss) from continuing operations before interest and taxes | 125,570 | (4,793 | ) | ||||
| Interest expense | 18,544 | 22,683 | |||||
| Interest income | (1,917 | ) | (1,666 | ) | |||
| Income (loss) from continuing operations before taxes | 108,943 | (25,810 | ) | ||||
| Taxes (benefit) on income from continuing operations | 13,839 | (41,551 | ) | ||||
| Income from continuing operations | 95,104 | 15,741 | |||||
| Operating loss from discontinued operations | (133 | ) | (587 | ) | |||
| Tax benefit on operating loss from discontinued operations | (31 | ) | (135 | ) | |||
| Loss from discontinued operations | (102 | ) | (452 | ) | |||
| Net income | $ | 95,002 | $ | 15,289 | |||
| Earnings per share: | |||||||
| Basic: | |||||||
| Income from continuing operations | $ | 2.08 | $ | 0.33 | |||
| Loss from discontinued operations | — | (0.01 | ) | ||||
| Net income | $ | 2.08 | $ | 0.32 | |||
| Diluted: | |||||||
| Income from continuing operations | $ | 2.07 | $ | 0.33 | |||
| Loss from discontinued operations | — | (0.01 | ) | ||||
| Net income | $ | 2.07 | $ | 0.32 | |||
| Weighted average common shares outstanding | |||||||
| Basic | 45,782 | 47,068 | |||||
| Diluted | 45,926 | 47,394 | |||||
| TELEFLEX INCORPORATED CONSOLIDATED BALANCE SHEETS (Unaudited) | |||||||
| March 30, 2025 | December 31, 2024 | ||||||
| (Dollars in thousands) | |||||||
| ASSETS | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 284,122 | $ | 290,188 | |||
| Accounts receivable, net | 464,523 | 459,495 | |||||
| Inventories | 643,972 | 600,133 | |||||
| Prepaid expenses and other current assets | 141,604 | 117,851 | |||||
| Prepaid taxes | 4,693 | 3,457 | |||||
| Total current assets | 1,538,914 | 1,471,124 | |||||
| Property, plant and equipment, net | 518,916 | 502,852 | |||||
| Operating lease assets | 108,340 | 108,912 | |||||
| Goodwill | 2,651,886 | 2,632,314 | |||||
| Intangible assets, net | 2,226,144 | 2,268,714 | |||||
| Deferred tax assets | 11,773 | 11,374 | |||||
| Other assets | 107,317 | 102,624 | |||||
| Total assets | $ | 7,163,290 | $ | 7,097,914 | |||
| LIABILITIES AND EQUITY | |||||||
| Current liabilities | |||||||
| Current borrowings | $ | 100,000 | $ | 100,000 | |||
| Accounts payable | 143,037 | 141,031 | |||||
| Accrued expenses | 150,856 | 143,167 | |||||
| Payroll and benefit-related liabilities | 108,900 | 151,263 | |||||
| Accrued interest | 17,020 | 5,338 | |||||
| Income taxes payable | 49,780 | 41,318 | |||||
| Other current liabilities | 106,316 | 67,243 | |||||
| Total current liabilities | 675,909 | 649,360 | |||||
| Long-term borrowings | 1,807,321 | 1,555,871 | |||||
| Deferred tax liabilities | 385,670 | 391,066 | |||||
| Pension and postretirement benefit liabilities | 20,304 | 20,185 | |||||
| Noncurrent liability for uncertain tax positions | 1,896 | 1,831 | |||||
| Noncurrent operating lease liabilities | 97,661 | 99,154 | |||||
| Other liabilities | 79,365 | 102,307 | |||||
| Total liabilities | 3,068,126 | 2,819,774 | |||||
| Commitments and contingencies | |||||||
| Total shareholders' equity | 4,095,164 | 4,278,140 | |||||
| Total liabilities and shareholders' equity | $ | 7,163,290 | $ | 7,097,914 | |||
| TELEFLEX INCORPORATED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | |||||||
| Three Months Ended | |||||||
| March 30, 2025 | March 31, 2024 | ||||||
| (Dollars in thousands) | |||||||
| Cash flows from operating activities of continuing operations: | |||||||
| Net income | $ | 95,002 | $ | 15,289 | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
| Loss from discontinued operations | 102 | 452 | |||||
| Depreciation expense | 19,409 | 15,928 | |||||
| Intangible asset amortization expense | 47,922 | 50,116 | |||||
| Deferred financing costs and debt discount amortization expense | 851 | 853 | |||||
| Pension settlement charge | — | 138,139 | |||||
| Fair value step up of acquired inventory sold | — | 1,722 | |||||
| Changes in contingent consideration | (1,795 | ) | 865 | ||||
| Stock-based compensation | 7,826 | 7,129 | |||||
| Asset impairment charge | — | 2,110 | |||||
| (Gain) loss on non-designated foreign currency forward contracts | (23,268 | ) | — | ||||
| Deferred income taxes, net | 372 | (58,282 | ) | ||||
| Interest benefit on swaps designated as net investment hedges | (4,239 | ) | (3,720 | ) | |||
| Other | (50 | ) | (118 | ) | |||
| Changes in assets and liabilities, net of effects of acquisitions and disposals: | |||||||
| Accounts receivable | (5,104 | ) | (9,549 | ) | |||
| Inventories | (29,489 | ) | (11,720 | ) | |||
| Prepaid expenses and other assets | (13,196 | ) | 7,352 | ||||
| Accounts payable, accrued expenses and other liabilities | (27,899 | ) | (50,610 | ) | |||
| Income taxes receivable and payable, net | 6,896 | 6,888 | |||||
| Net cash provided by operating activities from continuing operations | 73,340 | 112,844 | |||||
| Cash flows from investing activities of continuing operations: | |||||||
| Expenditures for property, plant and equipment | (30,011 | ) | (38,432 | ) | |||
| Payments for businesses and intangibles acquired, net of cash acquired | (90 | ) | (70 | ) | |||
| Insurance settlement proceeds | 6,307 | — | |||||
| Net proceeds on swaps designated as net investment hedges | — | 13,695 | |||||
| Purchase of investments | (5,000 | ) | — | ||||
| Net cash used in investing activities from continuing operations | (28,794 | ) | (24,807 | ) | |||
| Cash flows from financing activities of continuing operations: | |||||||
| Proceeds from new borrowings | 300,000 | — | |||||
| Reduction in borrowings | (49,125 | ) | (57,125 | ) | |||
| Repurchase of common stock | (300,000 | ) | — | ||||
| Net proceeds from share based compensation plans and related tax impacts | 7,348 | 1,750 | |||||
| Payments for contingent consideration | (56 | ) | (72 | ) | |||
| Dividends paid | (15,191 | ) | (16,001 | ) | |||
| Debt extinguishment, issuance and amendment fees | (2,500 | ) | — | ||||
| Net cash used in financing activities from continuing operations | (59,524 | ) | (71,448 | ) | |||
| Cash flows from discontinued operations: | |||||||
| Net cash used in operating activities | (246 | ) | (1,863 | ) | |||
| Net cash used in discontinued operations | (246 | ) | (1,863 | ) | |||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | 5,052 | (151 | ) | ||||
| Net (decrease) increase in cash, cash equivalents and restricted cash equivalents | (10,172 | ) | 14,575 | ||||
| Cash, cash equivalents and restricted cash equivalents at the beginning of the period | 327,650 | 222,848 | |||||
| Cash, cash equivalents and restricted cash equivalents at the end of the period | $ | 317,478 | $ | 237,423 | |||
Contacts:
Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
www.investors.teleflex.com
610-948-2836
| Last Trade: | US$127.46 |
| Daily Change: | -9.59 -7.00 |
| Daily Volume: | 512,970 |
| Market Cap: | US$5.920B |
April 30, 2025 April 01, 2025 March 27, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
